Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.
Lurie Children's Hospital, Chicago, Illinois, United States
Johns Hopkins Hospital and Children's Center, Baltimore, Maryland, United States
Rady Children's Hospital, San Diego, California, United States
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Ospedale Regionale di Locarno, Locarno, Switzerland
Hôpital du Valais, Sion, Switzerland
University of Utah, Salt Lake City, Utah, United States
The Cardiovascular Hospital, Heliopolis, Cairo, Egypt
Florida Orthopaedic Institute, Tampa, Florida, United States
Clinica Adventista Belgrano, Caba, Argentina
Hospital e Maternidade Dr Christovao da Gama S.A, Santo Andre, Brazil
Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz, Szekesfehervar, Hungary
Oregon Health & Science University, Portland, Oregon, United States
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Department of Neurology, Samsung Medical Center, Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.